Clinical trials: B Acute Lymphoblastic Leukemia, open to volunteers
B-cell Acute Lymphoblastic Leukemia
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
The researchers are doing this study to find out whether PK-targeted fludarabine is an effective Lymphodepletion (LD) chemotherapy approach for people with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) who will…
- Trial name
- NCT07223021
- Testing
- Fludarabine, Cyclophosphamide, CAR-T
- Where
- 6 sites in United States, Netherlands
- Volunteers
- 130 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Lymphoblastic Leukemia
2 Gy Total Body Irradiation As Part Of Conditioning Treatment For Patients With Acute Lymphoblastic Leukemia Undergoing CAR T Cell Therapy
The proposed research will compare the effects of TBI prior to CAR T cell infusion to the current standard of care using lymphodepletion.
- Trial name
- NCT07856758
- Testing
- CAR T cell therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Subjects on this study have a type of lymph gland cancer called Non-Hodgkin Lymphoma, acute lymphocytic leukemia, or chronic Lymphocytic Leukemia (these diseases will be referred to as "lymphoma" or "leukemia").
- Conditions
- Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia
- Trial name
- SAGAN (NCT01853631)
- Testing
- Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells, Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Baylor College of Medicine
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma
- Trial name
- NCT05334069
- Testing
- Questionnaire Administration, Biospecimen Collection
- Where
- 747 sites in United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Alliance for Clinical Trials in Oncology
B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
BEBT-908 in MEF2D-Rearranged Relapsed/Refractory or MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
This is a single-center, open-label, exploratory study evaluating ifupinostat hydrochloride (BEBT-908) in patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) with MEF2D rearrangement.
- Trial name
- NCT07854652
- Testing
- Ifupinostat Hydrochloride
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Hematologic Malignancy, Leukemia
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting.
- Conditions
- Hematologic Malignancy, Leukemia, Lymphoma, Acute Lymphocytic Leukemia
- Trial name
- NCT06131801
- Testing
- 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Acute Myeloid Leukemia, Myelodysplastic Syndromes
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transplantation for hematologic…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT03802695
- Testing
- OrcaGraft (Orca-Q)
- Where
- 12 sites in United States
- Volunteers
- 300 people
- Sponsor
- Orca Biosystems, Inc.
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
CAYA Cancer Retrospective Cohort Study
Despite advances in cancer treatment, significant disparities in outcomes persist between high-income countries (HICs) and low-and middle-income countries (LMICs).
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Young Adult Cancer, Adolescent Cancer
- Trial name
- NCT07246213
- Testing
- Retrospective Medical Record Review
- Where
- 7 sites in Armenia, Egypt and 4 more
- Volunteers
- 18,000 people
- Sponsor
- Resonance, Inc.
Cancer, Pediatric Cancer
CAYA Cancer Prospective Cohort Study
Cancer is a leading cause of illness and death among children, adolescents, and young adults(CAYAs), especially in low- and middle-income countries(LMICs), where access to timely diagnosis and treatment is often limited.
- Conditions
- Cancer, Pediatric Cancer, Lymphoblastic Lymphoma (LBL), Acute Lymphoblastic Leukemia (ALL)
- Trial name
- NCT07632014
- Where
- 6 sites in Armenia, Egypt and 3 more
- Volunteers
- 6,000 people
- Sponsor
- Resonance, Inc.
T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
The T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) and to WU-CART-007 as a therapy to induce complete…
- Trial name
- NCT06514794
- Testing
- WU-CART-007
- Where
- 18 sites in United States, Australia
- Volunteers
- 125 people
- Sponsor
- Allotera Therapeutics
B-Cell Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia
Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
This is a Phase 2 Study is to determine the efficacy and safety rate of B-Cell Acute Lymphoblastic Leukemia (B-ALL) participants in remission with minimal residual disease (MRD) after KTE-X19 CAR T-cell therapy
- Trial name
- NCT06144606
- Testing
- Tecartus
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
B-cell Acute Lymphoblastic Leukemia
Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia
This investigator-initiated, prospective, single-arm, phase I dose-escalation trial aims to evaluate the safety and tolerability of anti-CD19/CD22 dual-target cord blood-derived CAR-T cells in adult patients with…
- Trial name
- NCT07838714
- Testing
- Anti-CD19/CD22 Dual-Target Cord Blood CAR-T Cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Ruijin Hospital
Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)
Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL
This is a prospective, open-label, single-arm, umbrella phase 2 clinical trial enrolling 22 adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) B-cell acute lymphoblastic leukemia (ALL).
- Trial name
- Ph+ ALL-2026 (NCT07840976)
- Testing
- olverembatinib, Venetoclax, Inotuzumab Ozogamicin (IO)
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
ACUTE LYMPHOBLASTIC LEUKEMIA
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
This prospective, randomized, multicenter, open-label Phase 2 study is designed to evaluate the superiority of InO monotherapy vs ALLR3 after 1 cycle of induction treatment in paediatric participants (between 1 and <18 years)…
- Trial name
- NCT05748171
- Testing
- Inotuzumab ozogamicin, ALLR3
- Where
- 65 sites in Austria, Belgium and 13 more
- Volunteers
- 100 people
- Sponsor
- Pfizer
Acute Lymphoblastic Leukemia in Remission, Hodgkin Lymphoma in Remission
Obesity Treatment With Phentermine-Topiramate ER in AYA Surviving Leukemia and Lymphoma
This study is evaluating whether a weight-loss medication (PHEN/TOP) combined with healthy lifestyle counseling is safe, well tolerated, and can help reduce obesity in adolescents and young adults who are in remission from ALL…
- Conditions
- Acute Lymphoblastic Leukemia in Remission, Hodgkin Lymphoma in Remission, Non-Hodgkin Lymphoma in Remission, Cancer Survivorship
- Trial name
- NCT07790913
- Testing
- Phentermine/Topiramate ER, Health Behavior and Lifestyle Counseling
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- St. Jude Children's Research Hospital
B-cell Acute Lymphoblastic Leukemia
SNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
This study aims to evaluate the safety and pharmacokinetic profile of SNC116 in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia
- Trial name
- NCT07830238
- Testing
- SNC116
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Shanghai Simnova Biotechnology Co.,Ltd.
T-cell Acute Lymphoblastic Leukemia, T-Cell Lymphoblastic Lymphoma
A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
To learn if giving the study drugs calaspargase pegol-mknl and decitabine in combination with venetoclax can help to control relapsed/refractory T-ALL and T-LLy. The safety of this drug combination will also be studied.
- Trial name
- NCT06561074
- Testing
- Decitabine, Venetoclax, Calaspargase pegol-mknl
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma
Study of Out of Specification for Tisagenlecleucel
This study will evaluate the safety of tisagenlecleucel that is out of specification( OOS) for release as commercial product. Specifically, this study will evaluate the safety of CTL019 in the patients treated within the approved…
- Trial name
- NCT04094311
- Testing
- CTL019
- Where
- 55 sites in Canada, Japan
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals
T-cell Acute Lymphoblastic Leukemia
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
In this study, the investigators are hypothesizing that daratumumab-hyaluronidase will effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment with chemotherapy.
- Trial name
- NCT05289687
- Testing
- Daratumumab / Hyaluronidase Injection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Eastern Cooperative Oncology Group
Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL
A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
This is a phase II clinical study to evaluate the safety and efficacy of pCAR-19 B cell autologous infusion preparation in the treatment of CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.
- Conditions
- Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT05334823
- Testing
- pCAR-19B cells
- Where
- 16 sites in China
- Volunteers
- 100 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd